The four newest luminaries honored by the Medical Advertising Hall of Fame built sterling reputations as they advanced their fields. Joshua Slatko looks back on their success and on how each came to be synonymous with their particular niche of healthcare marketing
“New and improved” has entered this space. Alongside the existing compounds that are transforming the lives of patients with orphan ailments, a wave of incrementally better products is coming out. Noah Pines reviews the significant rare-disease market trends
As the Affordable Care Act rolls out, the behaviorists at MicroMass surveyed stakeholders about the impact on industry. Jessica Brueggeman sorts out the diverse views and asks: Can healthcare reform lead pharma to operationalize its patient focus?
Pharma has reduced the burden of disease. It can develop a condition-specific app. But getting people to take their medications as prescribed? That’s another matter. Larry Dobrow on why biopharma is backing mobile games for their potential to boost adherence and drive behavior change
The US Supreme Court has declined, without comment, to hear a closely watched appeal by former InterMune CEO Scott Harkonen on whether someone can be prosecuted for speaking truthfully about a drug.
Liberate Ideas and the American Academy of Physicians Assistants are rolling out the Liberate Health platform to give physician assistants more tools to communicate with patients
